Bodenstedt Matthias 4

What Happened

• Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (MLTX), disposed of 39,120 shares on June 22, 2026. The reported weighted‑average sale price was $22.04 per share, for aggregate proceeds of approximately $862,205. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: June 22, 2026 (reported on Form 4 filed June 23, 2026 — timely filing).
• Trade type: Sale (open‑market/private sale classification on the filing).
• Prices: Weighted average $22.04; individual sale prices ranged from $19.87 to $23.2049 (shares sold in multiple transactions).
• Total proceeds: ~$862,205.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnotes: (F1) Trade executed pursuant to a Rule 10b5‑1 trading plan adopted December 10, 2025. (F2) The filing reports a weighted average price and notes the seller will provide breakdown of shares sold at each price if requested by the SEC staff or the issuer/security holder.

Context

• A Rule 10b5‑1 plan indicates these sales were made under a pre‑arranged trading program, which helps insiders execute trades while reducing the risk of trading on material nonpublic information. Sales under such plans are common and are generally considered routine; they do not, by themselves, indicate the insider’s view of the company’s prospects.